BDBM627362 (S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)-2-(4-cyanobutoxy)-5-methylbenzyl)piperazine-2-carboxylic acid::US20230331675, Compound 18

SMILES Cc1cc(CN2CCNC[C@H]2C(O)=O)c(OCCCCC#N)cc1\C=C\c1cccc(-c2ccccc2)c1C#N

InChI Key InChIKey=SUAYPYIQIBEIGV-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 627362   

TargetProgrammed cell death 1 ligand/protein 1(Human)
Guangzhou Maxinovel Pharmaceuticals

US Patent
LigandPNGBDBM627362((S,E)-1-(4-(2-(2-Cyano-[1,1'-biphenyl]-3-yl)vinyl)...)
Affinity DataIC50: 22.2nMAssay Description:Homogeneous time-resolved fluorescence (HTRF) binding assay was used to determine the binding ability of the compound of the present disclosure to PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent